Evaluating the Accuracy of Microvessel Ultrasound Imaging for Detecting Extent of Disease in Patients With Angiosarcoma of the Skin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-31

Study Completion Date

2023-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the accuracy of a new ultrasound technology called microvessel imaging for detecting the extent of disease among patients with angiosarcoma of the skin. Microvessel ultrasound imaging uses high frequency waves to visualize vessels in the skin that are not easily seen using other imaging tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Staging Procedures to Diagnose Malignant Pleural Mesothelioma

NCT02648763

Mesothelioma Solitary Fibrous Tumor of the Pleura

TERMINATED

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

NCT05704283

Breast Carcinoma

RECRUITING EARLY_PHASE1

Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma

NCT02384473

Adult Soft Tissue Sarcoma Bone Sarcoma Retroperitoneal Sarcoma

COMPLETED EARLY_PHASE1

Patient Registry in Patients Undergoing Contrast-Enhanced Harmonic Endoscopic Ultrasound Imaging

NCT05717101

Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm

COMPLETED

Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma

NCT02968680

Cutaneous Melanoma Melanoma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To determine the accuracy of depicting extent of disease of cutaneous angiosarcoma before and after neoadjuvant treatment compared to clinical photographs, magnetic resonance imaging (MR) or positron emission tomography (PET)/computed tomography (CT) imaging and surgical pathology both on skin biopsies and surgical excision.

OUTLINE:

Patients undergo microvessel ultrasound imaging on study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Angiosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (microvessel ultrasound imaging)

Patients undergo microvessel ultrasound imaging on study.

Ultrasound Microvessel Imaging

Intervention Type DEVICE

Undergo microvessel ultrasound imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound Microvessel Imaging

Undergo microvessel ultrasound imaging

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

3D Ultrasound Microvessel Imaging UMI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Diagnosed with cutaneous angiosarcoma of the breast or scalp and scheduled for trimodality therapy
* Twenty one years of age or older